
HIMS Stock Forecast & Price Target
HIMS Analyst Ratings
Bulls say
Hims & Hers Health is a promising telehealth company with a strong track record of revenue growth and strategic partnerships in the healthcare industry. While there are concerns about profitability and potential legal risks, the company's focus on long-term growth and expansion into international markets bodes well for its future success. However, maintaining profitability and overcoming challenges in personalization and customer retention will be key areas to monitor for investors.
Bears say
Hims & Hers Health is facing several risks that may hinder its long-term growth potential and profitability. These risks include fierce competition, tighter regulatory scrutiny and changes, and the potential impact of a strategic partnership with Novo Nordisk on its business model. The company's recent partnership with Novo Nordisk may provide a near-term boost in revenue, but there are concerns about the viability of its compounded medication offerings and the potential for increased costs and customer attrition in the long run. Overall, the company's current financials and outlook suggest that it may struggle to maintain a competitive edge and achieve long-term profitability.
This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.
HIMS Analyst Forecast & Price Prediction
Start investing in HIMS
Order type
Buy in
Order amount
Est. shares
0 shares